Apellis Pharmaceuticals, Inc. (APLS) — Analyst outlook / Analyst consensus target is. Based on 25 analyst ratings, the consensus is bullish — 1 Strong Buy, 17 Buy, 6 Hold, 1 Sell.
The consensus price target is $33.50 (low: $19.00, high: $52.00), representing a downside of 18% from the current price $40.85.
Analysts estimate Earnings Per Share (EPS) of $-1.64 and revenue of $0.77B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.60 vs est $-1.64 (beat +2.6%). 2025: actual $0.18 vs est $0.26 (missed -30.9%). Analyst accuracy: 76%.
APLS Stock — 12-Month Price Forecast
$33.50
▼ -17.99% Downside
Average Price Target
Based on 25 Wall Street analysts offering 12-month price targets for Apellis Pharmaceuticals, Inc., the average price target is $33.50, with a high forecast of $52.00, and a low forecast of $19.00.
The average price target represents a -17.99% change from the last price of $40.85.
Highest Price Target
$52.00
Average Price Target
$33.50
Lowest Price Target
$19.00
APLS Analyst Ratings
Buy
Based on 25 analysts giving stock ratings to Apellis Pharmaceuticals, Inc. in the past 3 months
EPS Estimates — APLS
76%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual –$1.60
vs Est –$1.64
▲ 2.7% off
2025
Actual $0.18
vs Est $0.26
▼ 44.8% off
Profitability Outlook
Company has mixed profitability — some years profitable, some at a loss. EPS trend is improving.
Revenue Estimates — APLS
99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.781B
vs Est $0.767B
▲ 1.8% off
2025
Actual $1.004B
vs Est $1.005B
▼ 0.1% off
Revenue Trend
Moderate revenue growth trend. Analysts forecast revenue contraction ahead.
